{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002808","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.266100+00:00","generated_at":"2026-06-19T13:39:38.413087+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kintara Q2 net loss $3.5M; cash $4.9M; VAL-083 gets orphan status for DIPG","bullets":["Net loss of $3.5M vs $5.9M YoY; diluted EPS -$2.10 vs -$6.07.","Cash and equivalents $4.9M at Dec 31, 2022, down from $11.8M at June 30.","FDA granted Orphan Drug Designation for VAL-083 in DIPG; Fast Track for REM-001 in CMBC.","REM-001 program paused to conserve cash, expected savings of ~$3.0M through CY2023.","Regained Nasdaq minimum bid price compliance after 1-for-50 reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002808","json":"https://secwatch.observer/filing/0000950170-23-002808.json","markdown":"https://secwatch.observer/filing/0000950170-23-002808.md","text":"https://secwatch.observer/filing/0000950170-23-002808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023002808/0000950170-23-002808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023002808/ktra-20230214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:39:38.413087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1da5a61cc9ff6758cbb324dc345d16472f24b0a","claim":"TuHURA Biosciences, Inc./NV reported fiscal year 2023 second quarter ended December 31, 2022 results: net income net loss of approximately $3.5 million, or $2.10 per share, EPS $2.10 per share.","evidence_excerpt":"For the three months ended December 31, 2022, Kintara reported a net loss of approximately $3.5 million, or $2.10 per share, compared to a net loss of approximately $5.9 million, or $6.07 per share, for the three months ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023002808/0000950170-23-002808-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023 second quarter ended December 31, 2022"},{"label":"Net income","value":"net loss of approximately $3.5 million, or $2.10 per share"},{"label":"EPS","value":"$2.10 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}